Table 2.
irAEs During the Entire Observation Period
| Variables | Taking ICIs (N = 126) |
||
|---|---|---|---|
| Prevaccination | Postvaccination | During the Entire Observation Period | |
| irAEs | |||
| Grade, n (%) | |||
| Any grade, | 26 (20.6) | 7 (5.6) | 33 (26.2) |
| Grades 1–2 | 21 (16.7) | 6 (4.8) | 27 (21.4) |
| Grade 3 | 5 (4.0) | 1 (0.8) | 6 (4.8) |
| Grades 4–5 | 0 (0) | 0 (0) | 0 (0) |
| Type, n (%) | |||
| Skin | 9 (7.1) | 0 (0) | 9 (7.1) |
| Gastrointestinal | 5 (4.0) | 2 (1.6) | 7 (5.6) |
| Hepatic | 0 (0) | 0 (0) | 0 (0) |
| Lung | 1 (0.8) | 3 (2.4) | 4 (3.2) |
| Endocrine | 14 (11.1) | 2 (1.6) | 16 (12.7) |
| Musculoskeletal/rheumatologic | 1 (0.8) | 0 (0) | 1 (0.8) |
| Renal | 1 (0.8) | 1 (0.8) | 2 (1.6) |
| Nervous system (neurologic) | 0 (0) | 0 (0) | 0 (0) |
| Hematologic | 0 (0) | 0 (0) | 0 (0) |
| Cardiovascular | 0 (0) | 0 (0) | 0 (0) |
| Ocular | 0 (0) | 0 (0) | 0 (0) |
| ICI treatment discontinuation due to irAEs | 2 (1.6) | 2 (1.6) | 4 (3.2) |
ICI, immune checkpoint inhibitor; irAE, immune-related adverse event.